“We are excited to work with Amgen on a highly important scientific problem,” said Joshua Salafsky, Ph.D., Founder and CSO of Biodesy. “We appreciate the interest from pharmaceutical partners like Amgen in using our technology for drug discovery applications. We have now established multiple commercial partnerships and we look forward to launching a commercial system next year.”
Biodesy is developing the first products and systems to rapidly and inexpensively measure both protein structure and function in real time, with applications including drug discovery, structural biology, and clinical biomarkers. Biodesy has developed a unique and highly sensitive technology for detecting conformational change in proteins and other biological molecules. Its technology, based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time. Since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how our bodies function and respond to treatments. Biodesy is located in South San Francisco, California. For more information, please visit www.biodesy.com.